Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Total Liabilities (2023 - 2026)

ArriVent BioPharma has reported Total Liabilities over the past 4 years, most recently at $25.3 million for Q1 2026.

  • Quarterly results put Total Liabilities at $25.3 million for Q1 2026, up 95.44% from a year ago — trailing twelve months through Mar 2026 was $25.3 million (up 95.44% YoY), and the annual figure for FY2025 was $25.9 million, up 50.08%.
  • Total Liabilities reached $25.3 million in Q1 2026 per AVBP's latest filing, down from $25.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $132.6 million in Q3 2023 and bottomed at $10.1 million in Q1 2024.
  • Median Total Liabilities over the past 4 years was $19.6 million (2025), compared with a mean of $40.0 million.
  • The largest annual shift saw Total Liabilities crashed 89.7% in 2024 before it soared 95.44% in 2026.
  • Over 4 years, Total Liabilities stood at $11.8 million in 2023, then skyrocketed by 46.5% to $17.3 million in 2024, then skyrocketed by 50.08% to $25.9 million in 2025, then fell by 2.43% to $25.3 million in 2026.
  • Business Quant data shows Total Liabilities for AVBP at $25.3 million in Q1 2026, $25.9 million in Q4 2025, and $21.6 million in Q3 2025.